A recent Haematology digest,
as sent to subscribers

Study Type: Case series (n=4)

Key Question: Can CD19 CAR-T therapy be effective and safe in pemphigus vulgaris patients without lymphodepleting pre-conditioning?

Key Findings:

• All 4 patients showed significant improvement in pemphigus disease area index scores following resecabtagene autoleucel infusion
• Safety profile was favourable with only one grade 1 cytokine release syndrome episode and no immune effector cell-associated neurotoxicity
• B cell depletion occurred in all patients (3/4 achieved B cell aplasia), with CAR-T expansion comparable to lymphodepleted patients in other autoimmune diseases

Clinical Relevance: This suggests CAR-T therapy could potentially treat severe autoimmune conditions without the toxicity and resource burden of lymphodepleting chemotherapy, though pemphigus vulgaris management typically falls outside routine haematology practice.

Limitations: Extremely small sample size (n=4) with short-term follow-up data only reported.

Study Type: Experimental study using genetically engineered mouse models with correlative human AML analysis

Key Question: How do IDH1 mutations specifically impair neutrophil differentiation in pre-leukemic haematopoiesis?

Key Findings:

• IDH1-mutant AML cases showed neutrophil lineage-specific DNA methylation changes and severely impaired neutrophil differentiation compared to IDH2-mutant cases
• Mouse models with heterozygous IDH1 mutations demonstrated cell-intrinsic neutrophil differentiation block via repression of myeloid transcription programs, particularly Cebpe expression
• Differentiation block was reversible through Cebpa overexpression or hypomethylating agent treatment, restoring neutrophil maturation

Clinical Relevance: This explains why IDH1 mutations are strongly associated with myeloid malignancies and suggests hypomethylating agents may specifically benefit IDH1-mutant AML patients with neutropenia.

Limitations: Pre-clinical mouse model findings require validation in human IDH1-mutant AML patients before clinical translation.

Study Type: Experimental study with metabolomics profiling and functional assays

Key Question: How does metabolism, particularly L-carnitine-driven fatty acid oxidation, regulate human hematopoietic stem and progenitor cell function?

Key Findings:

• Low-input mass spectrometry detected >80 metabolites across 13 bone marrow cell types using ~10,000 cells per sample
• L-carnitine enhances fatty acid oxidation via PPARA-TFEB signalling, promoting mitochondrial metabolism and autophagy in HSPCs
• L-carnitine supplementation improved stem cell function in primary CD34+ cells from both healthy donors and aplastic anaemia patients

Clinical Relevance: This identifies L-carnitine as a potential therapeutic target for improving haematopoietic stem cell transplantation outcomes and treating bone marrow failure syndromes within NHS haematology services.

Limitations: The study does not specify sample sizes for functional assays or provide quantitative measures of improvement in stem cell function.

Study Type: Experimental study using CRISPR-Cas9 mutagenesis screening

Key Question: Can selective disruption of polycomb repressive complex components reactivate fetal haemoglobin production without complete loss of cellular function?

Key Findings:

• CRISPR screening identified EZH2 exon 14 skipping (EZH2Δ14) as a mechanism to relieve HbF repression while maintaining cellular fitness
• EZH2Δ14 retains partial H3K27 methylation activity and selective gene repression, demonstrating functional specificity
• Mouse models with human β-globin genes confirmed EZH2-mediated HbF control pathways are conserved

Clinical Relevance: This approach could offer a more targeted therapeutic strategy for sickle cell disease and β-thalassemia by inducing HbF without the broad toxicity associated with complete polycomb complex inhibition.

Limitations: The study is conducted in experimental models and requires validation in human clinical trials to assess safety and efficacy.

Study Type: Experimental laboratory study using CRISPR interference screening and chromatin analysis

Key Question: How do the histone methyltransferases DOT1L and EZH2 cooperate to maintain germinal center B cell identity in GCB-DLBCL while preventing plasma cell differentiation?

Key Findings:

• DOT1L regulates chromatin-bound non-canonical PRC1 complexes and controls H2AK119 monoubiquitination at promoters co-occupied by H3K27me3
• USP7 was identified as a direct DOT1L target whose downregulation increased sensitivity to EZH2 inhibition in multiple GCB-DLBCL cell lines
• DOT1L inhibition leads to loss of H2AK119ub1 and derepression of plasma cell signature genes, promoting differentiation toward an anti-proliferative plasma cell-like state

Clinical Relevance: This provides mechanistic rationale for combination targeting of DOT1L and EZH2 pathways in GCB-DLBCL treatment strategies, potentially relevant for UK patients with chemotherapy-refractory disease.

Limitations: Laboratory-based study requiring validation in primary patient samples and clinical trials.

Study Type: Preclinical experimental study with correlative clinical data

Key Question: What non-genetic mechanisms drive resistance to BTK inhibitors in B-cell lymphomas?

Key Findings:

• IL-16 cytokine secretion mediates BTK inhibitor resistance across multiple B-cell lymphoma subtypes (MZL, MCL, CLL, ABC-DLBCL) through CD9/PI3Kδ pathway activation
• Elevated serum IL-16 levels were found in ibrutinib-refractory CLL patients lacking BTK/PLCG2 mutations
• Targeting the IL-16/CD9/PI3K axis restored sensitivity to both BTK inhibitors and R-CHOP in preclinical models

Clinical Relevance: This identifies a novel biomarker and therapeutic target for BTK inhibitor resistance that affects multiple lymphoma types treated in UK haematology practice, potentially explaining treatment failure in patients without known resistance mutations.

Limitations: Primarily preclinical data with limited clinical validation in a small patient cohort.

Study Type: Laboratory-based mechanistic study using genetically modified megakaryocyte cell lines

Key Question: How does integrin αIIbβ3 deficiency affect platelet production in Glanzmann thrombasthenia patients?

Key Findings:

• 50% (8/16) of GT patients had platelet counts at lower end of normal range, suggesting mild thrombocytopenia
• Both αIIbβ3-deficient and constitutively-active variants showed reduced proplatelet formation in multiple culture systems
• Integrin αIIbβ3 deficiency impaired serine metabolism and downregulated SLC3A2 (CD98hc) amino acid transporter, which was corrected by wild-type ITGB3 re-expression

Clinical Relevance: Challenges the established view that GT patients have normal platelet counts and identifies a novel metabolic mechanism linking integrin function to thrombopoiesis, potentially informing thrombocytopenia evaluation in UK haematology practice.

Limitations: Study relies on immortalised cell line models rather than primary patient megakaryocytes, limiting direct clinical translation.

Study Type: Prespecified subgroup analysis from randomized controlled trial (AZALEA-TIMI 71)

Key Question: Does prior oral anticoagulation experience influence bleeding risk with the factor XI inhibitor abelacimab in atrial fibrillation patients?

Key Findings:

• Prior OAC experience modified bleeding risk in atrial fibrillation patients
• Abelacimab reduced bleeding consistently regardless of prior OAC exposure
• Greatest absolute bleeding reduction benefit occurred in OAC-naïve patients

Clinical Relevance: Factor XI inhibitors represent a potential new anticoagulation class for AF patients, with this analysis suggesting particular benefit for treatment-naïve patients who might otherwise face higher bleeding risk.

Limitations: Abstract provides insufficient detail on effect sizes, patient numbers, or specific bleeding outcomes measured.